Pfizer Licenses Three Starna In Vivo CAR T Programs

Pfizer signed an exclusive license for three pre-IND autoimmune in vivo CAR-T programs from Shanghai-based Starna Therapeutics. Pfizer will pay $330 million upfront; Starna can receive up to $2.3 billion in contingent development and…




